NumerixS Investment Technologies’s BioMarin Pharmaceuticals BMRN Stock Holding History

NumerixS Investment Technologies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,400	Closed	-$120K	–	1018
2019 Q2	$120K	Sell	1,400 -6,600	-83%	-$565K	0.03%	541
2019 Q1	$702K	Buy	8,000 +5,288	+195%	+$490K	0.09%	264
2018 Q4	$227K	Buy	+2,712	New	+$258K	0.07%	304
2018 Q1	–	Sell	-2,500	Closed	-$223K	–	1048
2017 Q4	$223K	Sell	2,500 -7,099	-74%	-$617K	0.05%	430
2017 Q3	$893K	Buy	9,599 +8,899	+1,271%	+$786K	0.2%	111
2017 Q2	$64K	Buy	+700	New	+$63.7K	0.01%	924
2016 Q4	–	Sell	-4,100	Closed	-$379K	–	1129
2016 Q3	$379K	Buy	4,100 +400	+11%	+$37.7K	0.05%	464
2016 Q2	$288K	Sell	3,700 -42,919	-92%	-$3.65M	0.04%	587
2016 Q1	$3.85M	Buy	+46,619	New	+$3.79M	0.44%	34
2015 Q4	–	Sell	-28,693	Closed	-$3.02M	–	773
2015 Q3	$3.02M	Buy	+28,693	New	+$3.83M	0.35%	53
2015 Q2	–	Sell	-6,000	Closed	-$748K	–	631
2015 Q1	$748K	Buy	+6,000	New	+$636K	0.14%	197

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

NumerixS Investment Technologies's BMRN Position: Q3 2019 in Review

NumerixS Investment Technologies sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 1,400 shares — an estimated $120K sold.

NumerixS Investment Technologies first reported a position in BMRN in Q1 2015 and held it in 11 quarters. The position peaked at $3.85M in Q1 2016. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

NumerixS Investment Technologies reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
NumerixS Investment Technologies sold 1,400 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $120K.
NumerixS Investment Technologies first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 11 quarters.
NumerixS Investment Technologies's BioMarin Pharmaceuticals position peaked at $3.85M in Q1 2016.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on NumerixS Investment Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.